Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Feb;9(2):151-161.
doi: 10.1002/cpdd.699. Epub 2019 May 23.

Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone

Sauzanne Khalilieh  1 , Ka L Yee  1 , Rosa I Sanchez  1 , Kate Vaynshteyn  1 , Li Fan  1 , Shawn Searle  2 , Mohammed Bouhajib  3 , Marian Iwamoto  1
Affiliations
Clinical Trial

Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone

Sauzanne Khalilieh et al. Clin Pharmacol Drug Dev. 2020 Feb.

Abstract

Doravirine is a novel nonnucleoside reverse transcriptase inhibitor indicated for the treatment of HIV type 1 infection. A subset of people living with HIV receives methadone for the treatment of opioid addiction. The current study (NCT02715700) was an open-label, multiple-dose, drug interaction study in participants on a methadone maintenance program to investigate potential drug-drug interactions between doravirine and methadone. Participants received a stable methadone maintenance dose of 20 to 180 mg once daily for 14 days prior to day 1 and remained on their maintenance dose over days 1 through 7. On days 2 through 6, an oral dose of doravirine 100 mg was coadministered. For doravirine and methadone pharmacokinetic analysis, blood samples were collected before dosing through 24 hours after dosing. Fourteen participants were enrolled; all participants completed the study. For R-methadone, geometric least squares mean ratios (90% confidence intervals) for dose-normalized area under the plasma concentration-time curve from time zero to 24 hours, plasma concentration at 24 hours, and maximum plasma concentration ([methadone + doravirine]/methadone alone) were 0.95 (0.90-1.01), 0.95 (0.88-1.03), and 0.98 (0.93-1.03), respectively. For doravirine, based on a comparison with historical data, modest decreases in area under the plasma concentration-time curve from time zero to 24 hours, plasma concentration at 24 hours, and maximum plasma concentration were observed after coadministration of doravirine and methadone; geometric least squares mean ratios ([methadone + doravirine]/doravirine alone [90% confidence intervals]) were 0.74 (0.61-0.90), 0.80 (0.63-1.03), and 0.76 (0.63-0.91), respectively. Coadministration of doravirine and methadone was generally well tolerated. No serious adverse events occurred, and there were no discontinuations. In conclusion, coadministration of methadone and doravirine did not have a clinically meaningful effect on the pharmacokinetic profile of either agent.

Keywords: doravirine; drug-drug interactions; methadone; pharmacokinetics.

PubMed Disclaimer

References

    1. Centers for Disease Control and Prevention. HIV Surveillance Report - Diagnoses of HIV Infection in the United States and Dependent Areas, 2016. https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveil.... Published 2016. Accessed January 23, 2019.
    1. Mimiaga MJ, Reisner SL, Grasso C, et al. Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS Research Network of Integrated Clinical Systems cohort. Am J Public Health. 2013;103(8):1457-1467.
    1. American Society of Addiction Medicine (ASAM). The ASAM National Practice Guideline For the Use of Medications in the Treatment of Addiction Involving Opioid Use. https://www.asam.org/docs/default-source/practice-support/guidelines-and.... Published 2015. Accessed January 23, 2019.
    1. Stein MD, Urdaneta ME, Clarke J, et al. Use of antiretroviral therapies by HIV-infected persons receiving methadone maintenance. J Addict Dis. 2000;19(1):85-94.
    1. Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol. 2013;6(3):249-269.

Publication types

MeSH terms